Successful Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial Infection with Meropenem and Cefoperazone Sodium Sulbactam: A Case Report

Wenke Ma,1 Chao Zhang,1 Bei He,1 Xinwen Lv,1 Peng Luo2 1Department of Neurosurgery, Baoji Central Hospital, Baoji, Shaanxi, People’s Republic of China; 2Department of Neurosurgery, The First Affiliated Hospital of Air Force Medical University, Xi’an, Shaanxi, People’s Republic of ChinaCorrespondence: Xinwen Lv, Department of Neurosurgery, Baoji Central Hospital, Baoji, Shaanxi, 721008, People’s Republic of China, Email [email protected] Peng Luo, Department of Neurosurgery, The First Affiliated Hospital of Air Force Medical University, Xi’an, Shaanxi, 710032, People’s Republic of China, Email [email protected]: Acinetobacter baumannii intracranial infections, especially those caused by multidrug-resistant (MDR) or extensively drug-resistant (XDR) strains, have posed an increasing challenge to treatment because of poor drug permeability through the blood–brain barrier (BBB) and increased bacterial drug resistance. Therefore, we aimed to explore a therapeutic schedule for Acinetobacter baumannii intracranial infection.Case Presentation: We reported a case of intracranial infection caused by XDR A. baumannii after severe traumatic brain injury, cerebrospinal fluid (CSF) rhinorrhea, and severe pneumonia that was successfully treated with meropenem and cefoperazone sodium sulbactam.Conclusion: This case illustrated that meropenem combined with cefoperazone sodium sulbactam could still be a therapeutic option against intracranial XDR A. baumannii infection.Keywords: intracranial infection, Acinetobacter baumannii, extensively drug-resistant, meropenem, cefoperazone sodium sulbactam

Publication Details

Journal
Dove Medical Press (Taylor and Francis Group)
Published
2025-04-04
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Successful Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial Infection with Meropenem and Cefoperazone Sodium Sulbactam: A Case Report

Dove Medical Press (Taylor and Francis Group)
Antibiotic Resistance in Bacteria
article

Successful Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial Infection with Meropenem and Cefoperazone Sodium Sulbactam: A Case Report

article en

Abstract

Wenke Ma,1 Chao Zhang,1 Bei He,1 Xinwen Lv,1 Peng Luo2 1Department of Neurosurgery, Baoji Central Hospital, Baoji, Shaanxi, People’s Republic of China; 2Department of Neurosurgery, The First Affiliated Hospital of Air Force Medical University, Xi’an, Shaanxi, People’s Republic of ChinaCorrespondence: Xinwen Lv, Department of Neurosurgery, Baoji Central Hospital, Baoji, Shaanxi, 721008, People’s Republic of China, Email [email protected] Peng Luo, Department of Neurosurgery, The First Affiliated Hospital of Air Force Medical University, Xi’an, Shaanxi, 710032, People’s Republic of China, Email [email protected]: Acinetobacter baumannii intracranial infections, especially those caused by multidrug-resistant (MDR) or extensively drug-resistant (XDR) strains, have posed an increasing challenge to treatment because of poor drug permeability through the blood–brain barrier (BBB) and increased bacterial drug resistance. Therefore, we aimed to explore a therapeutic schedule for Acinetobacter baumannii intracranial infection.Case Presentation: We reported a case of intracranial infection caused by XDR A. baumannii after severe traumatic brain injury, cerebrospinal fluid (CSF) rhinorrhea, and severe pneumonia that was successfully treated with meropenem and cefoperazone sodium sulbactam.Conclusion: This case illustrated that meropenem combined with cefoperazone sodium sulbactam could still be a therapeutic option against intracranial XDR A. baumannii infection.Keywords: intracranial infection, Acinetobacter baumannii, extensively drug-resistant, meropenem, cefoperazone sodium sulbactam

Dove Medical Press (Taylor and Francis Group)
National Natural Science Foundation of China
Openalex Percentile: Top 57%
Antibiotic Resistance in Bacteria
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.